Development of cancer-specific monoclonal antibodies against glycoproteins

Research output: Contribution to journalArticlepeer-review

Abstract

Many strategies have been tried to produce monoclonal antibodies (mAbs); however, there have been several problems about focusing on molecular targets and screening methods. For instance, the high tumor/normal ratio of antigen expression using DNA microarray has been thought to be important when we determine the molecular targets for antibody-drug. Although many antigens are expressed highly in tumors, those antigens have been removed from the candidates of antibody-drug targets because they were also expressed in normal tissues. We recently established a novel technology to produce a cancer-specific monoclonal antibody (CasMab). The post-translational difference such as glycans can be utilized to produce the CasMab, although the protein possesses the same amino acid sequence in both cancer and normal cells. We have already produced CasMabs against several glycoproteins such as podoplanin, which is expressed in both cancer and normal cells. Those CasMabs possess antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) in vitro and anti-tumor effect in xenograft models in vivo. In conclusion, the CasMab technology is the platform to develop cancer-specific mAbs, which could attack only cancer cells without side effects.

Original languageEnglish
Pages (from-to)150-154
Number of pages5
JournalFolia Pharmacologica Japonica
Volume155
Issue number3
DOIs
Publication statusPublished - 2020

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Development of cancer-specific monoclonal antibodies against glycoproteins'. Together they form a unique fingerprint.

Cite this